GL
AQST icon

Graypoint LLC’s Aquestive Therapeutics AQST Stock Holding History

Graypoint LLC’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-413,817
Closed -$1.08M – 299
2022
Q1 		$1.08M Buy
+413,817
New +$1.21M 0.11% 130

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Graypoint LLC's AQST Position: Q2 2022 in Review

Graypoint LLC sold out of Aquestive Therapeutics (AQST) in Q2 2022, closing a stake of 413,817 shares — an estimated $1.08M sold.

Graypoint LLC first reported a position in AQST in Q1 2022 and held it in 1 quarter. The position peaked at $1.08M in Q1 2022. 45 funds tracked by Wall St. Rank hold AQST as of Q2 2022.

  • Graypoint LLC reported no remaining Aquestive Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Graypoint LLC sold 413,817 Aquestive Therapeutics shares in Q2 2022, an estimated $1.08M.
  • Graypoint LLC first reported a position in Aquestive Therapeutics in Q1 2022 and held it in 1 quarter.
  • Graypoint LLC's Aquestive Therapeutics position peaked at $1.08M in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2022.

Based on Graypoint LLC's 13F filing for Q2 2022, filed 1 Aug 2022.